About POPLINE Services Tools Contact Us Search POPLINE View Cart
Your search found 1 record(s).
New Basic Search    |     New Advanced Search    |     POPLINE Document Delivery Policy

1.
Peer Reviewed

Title: The true cost differential between mifepristone and misoprostol and misoprostol-alone regimens for medical abortion.
Author: Creinin MD; Shore E; Balasubramanian S; Harwood B
Source: Contraception. 2005;71:26-30.
Abstract: Our objective was to evaluate relative differences in direct and total (direct and indirect) costs for medical abortion regimens using mifepristone and misoprostol or misoprostol alone. We created formulas to evaluate relative differences in costs in the United States, Chennai (Madras), India, and a hypothetical developing country based on published protocols and efficacy data. Follow-up visits and suction aspiration procedures in the United States were evaluated over a range of costs. American indirect costs were estimated using earning data. Indirect costs in India and the hypothetical developing country were based on mifepristone cost differences between the United States and India. Although mifepristone costs US$83.33 for every 200-mg tablet in the United States, the actual excess cost of using a mifepristone regimen, as compared with a misoprostol-alone regimen, is only US$22 to US$32. The actual cost of a mifepristone regimen is lower than that of a misoprostol-alone regimen in India. In a hypothetical developing country, a mifepristone regimen is likely to be less expensive than regimens using misoprostol alone. Because of the higher efficacy of medical abortion regimens using mifepristone and misoprostol and the need for fewer follow-up evaluations, such regimens are less expensive or only minimally more expensive than those using misoprostol alone. (author's)
Language: English

Keywords:
UNITED STATES | INDIA | RESEARCH REPORT | COST BENEFIT ANALYSIS | MISOPROSTOL | RU-486 | Developed Countries | North America | Americas | Asia, Southern | Asia | Developing Countries | Quantitative Evaluation | Evaluation | Prostaglandins, Synthetic | Prostaglandins | Endocrine System | Physiology | Biology | Hormone Antagonists | Hormones
Document Number: 279505   Notification
Johns Hopkins Bloomberg School of Public Health Center for Communication Programs Information & Knowledge for Optimal Health (INFO) Project
111 Market Place Suite 310, Baltimore, MD 21202
Phone: 410-659-6300    Fax: 410-659-6266    
Security & Privacy Policy
Icon Depicting USAID Seal